SG11201809396SA - A specific trifluoroethyl quinoline analogue for use in the treatment of apds - Google Patents
A specific trifluoroethyl quinoline analogue for use in the treatment of apdsInfo
- Publication number
- SG11201809396SA SG11201809396SA SG11201809396SA SG11201809396SA SG11201809396SA SG 11201809396S A SG11201809396S A SG 11201809396SA SG 11201809396S A SG11201809396S A SG 11201809396SA SG 11201809396S A SG11201809396S A SG 11201809396SA SG 11201809396S A SG11201809396S A SG 11201809396SA
- Authority
- SG
- Singapore
- Prior art keywords
- ucb
- international
- apds
- ipd
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608797.5A GB201608797D0 (en) | 2016-05-19 | 2016-05-19 | Therapeutic use |
| PCT/EP2017/061567 WO2017198590A1 (en) | 2016-05-19 | 2017-05-15 | A specific trifluoroethyl quinoline analogue for use in the treatment of apds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809396SA true SG11201809396SA (en) | 2018-11-29 |
Family
ID=56369612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809396SA SG11201809396SA (en) | 2016-05-19 | 2017-05-15 | A specific trifluoroethyl quinoline analogue for use in the treatment of apds |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190209567A1 (es) |
| EP (1) | EP3458065A1 (es) |
| JP (1) | JP2019516703A (es) |
| KR (1) | KR20190009790A (es) |
| CN (1) | CN109152783A (es) |
| AR (1) | AR108500A1 (es) |
| AU (1) | AU2017267172A1 (es) |
| BR (1) | BR112018072450A2 (es) |
| CA (1) | CA3023974A1 (es) |
| CL (1) | CL2018003281A1 (es) |
| CO (1) | CO2018013559A2 (es) |
| EA (1) | EA201892638A1 (es) |
| GB (1) | GB201608797D0 (es) |
| IL (1) | IL262943A (es) |
| MX (1) | MX2018013770A (es) |
| RU (1) | RU2018144187A (es) |
| SG (1) | SG11201809396SA (es) |
| WO (1) | WO2017198590A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
| JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体の使用 |
| PE20181086A1 (es) | 2015-09-11 | 2018-07-05 | Dana Farber Cancer Inst Inc | Acetamida tienotrizolodiazepinas y usos de las mismas |
| CA2996974A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| EP3380100A4 (en) | 2015-11-25 | 2019-10-02 | Dana-Farber Cancer Institute, Inc. | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF |
| GB201708856D0 (en) | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
| US20170151264A1 (en) * | 2014-05-27 | 2017-06-01 | Almirall, S.A. | Combination |
-
2016
- 2016-05-19 GB GBGB1608797.5A patent/GB201608797D0/en not_active Ceased
-
2017
- 2017-05-15 CN CN201780030825.XA patent/CN109152783A/zh active Pending
- 2017-05-15 EP EP17723388.9A patent/EP3458065A1/en not_active Withdrawn
- 2017-05-15 JP JP2018560052A patent/JP2019516703A/ja active Pending
- 2017-05-15 WO PCT/EP2017/061567 patent/WO2017198590A1/en unknown
- 2017-05-15 EA EA201892638A patent/EA201892638A1/ru unknown
- 2017-05-15 CA CA3023974A patent/CA3023974A1/en not_active Abandoned
- 2017-05-15 US US16/099,537 patent/US20190209567A1/en not_active Abandoned
- 2017-05-15 BR BR112018072450-5A patent/BR112018072450A2/pt not_active Application Discontinuation
- 2017-05-15 AU AU2017267172A patent/AU2017267172A1/en not_active Abandoned
- 2017-05-15 MX MX2018013770A patent/MX2018013770A/es unknown
- 2017-05-15 KR KR1020187036873A patent/KR20190009790A/ko not_active Application Discontinuation
- 2017-05-15 RU RU2018144187A patent/RU2018144187A/ru not_active Application Discontinuation
- 2017-05-15 SG SG11201809396SA patent/SG11201809396SA/en unknown
- 2017-05-17 AR ARP170101315A patent/AR108500A1/es unknown
-
2018
- 2018-11-12 IL IL262943A patent/IL262943A/en unknown
- 2018-11-19 CL CL2018003281A patent/CL2018003281A1/es unknown
- 2018-12-13 CO CONC2018/0013559A patent/CO2018013559A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018144187A3 (es) | 2020-06-19 |
| EP3458065A1 (en) | 2019-03-27 |
| CN109152783A (zh) | 2019-01-04 |
| AU2017267172A1 (en) | 2018-12-13 |
| IL262943A (en) | 2018-12-31 |
| JP2019516703A (ja) | 2019-06-20 |
| CL2018003281A1 (es) | 2019-01-25 |
| KR20190009790A (ko) | 2019-01-29 |
| BR112018072450A2 (pt) | 2019-02-19 |
| EA201892638A1 (ru) | 2019-06-28 |
| GB201608797D0 (en) | 2016-07-06 |
| US20190209567A1 (en) | 2019-07-11 |
| WO2017198590A1 (en) | 2017-11-23 |
| AR108500A1 (es) | 2018-08-29 |
| CO2018013559A2 (es) | 2019-02-28 |
| RU2018144187A (ru) | 2020-06-19 |
| MX2018013770A (es) | 2019-03-21 |
| CA3023974A1 (en) | 2017-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809396SA (en) | A specific trifluoroethyl quinoline analogue for use in the treatment of apds | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201900482SA (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201901409YA (en) | Polymerizing composition, method of manufacture thereof and articles comprising the same | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806852PA (en) | Protein purification | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201901468SA (en) | Antibodies with reduced binding to process impurities | |
| SG11201810786RA (en) | [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201907159SA (en) | Treatment of hidradenitis suppurativa | |
| SG11201903602RA (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201805900YA (en) | Inhibition of allergic reaction using an il-33 inhibitor | |
| SG11201808650QA (en) | Methods of treating ocular conditions |